跳到正文
原文
MedPage Today·· 8 天前精选AI 评分85

细胞疗法在早期试验中逆转膝关节骨关节炎损伤

Cell Therapy for Knee Osteoarthritis Reverses Damage in Early Trial

AI 导读

一项针对膝关节骨关节炎的细胞疗法OSCA在IIa期试验中显著改善症状并逆转关节损伤,可能成为首个真正意义上的治疗手段。

推荐理由

研究显示细胞疗法在早期试验中显著改善症状并逆转关节损伤,可能成为首个真正意义上的治疗手段。

正文 · 原文

— It won't be cheap, but could be the disease-modifying therapy the field has long sought

by John Gever, Contributing Writer, MedPage Today

November 11, 2026 • 3 min read

ORLANDO -- A cell-based therapy for knee osteoarthritis (OA) called OSCA not only improved patients' symptoms in a phase IIa trial and appeared safe, but also showed signs of reversing joint damage within a few months, a researcher reported here.

Standard evaluations including the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) and Knee Osteoarthritis Outcomes Score (KOOS) showed that a single treatment reduced pain levels by half in the 6-month study, according to Jae-Young Park, MD, PhD, of CHA University in Seongnam, Korea.

But perhaps more importantly, MRI findings at month 6 indicated that some cartilage had regenerated and marrow abnormalities were resolving, he told attendees during a late-breaking abstract session at the American College of Rheumatology's annual meeting.

Orthopedic surgeons should pay close attention: If these results are duplicated with further testing, the treatment could be the first genuine disease-modifying therapy for knee OA, potentially making arthroplasty a quaint relic of a barbaric era in medicine.

OSCA is shorthand for a combination of cord blood-derived mesenchymal stem cells, dubbed osiramestrocel (OS), and cartilage acellular matrix (CAM) taken from pigs, Park explained. He described the proposed mechanism of action as targeting not only the synovium, but also subchondral bone and sensory neurons. The hoped-for result is decreased inflammation, less pain, and structural improvement.

The phase IIa trial tested single doses of this product, injected into the knee joint, in 113 patients randomized equally among two dosing levels (50 or 100 million cells per injection) or placebo. Technically, safety was the primary focus in this early study, with pain, function, structural change, and biomarker effects as exploratory outcomes.

Mean patient age was about 62 and some two-thirds were women. Body mass index values averaged about 25 (which may raise questions about generalizability to the U.S. and other countries where obesity is more common). At baseline, self-reported pain scores on a 100-point scale averaged roughly 67, with mean WOMAC and KOOS values of about 55 and 50, respectively.

Three patients in the lower-dose group and eight receiving the higher dose experienced injection-site reactions, but no other important treatment-related adverse events were noted. Discounting the injection-site reactions, numbers of treatment-emergent adverse events were similar across the three study arms.

Those data may have been the study's primary object, but Park spent most of his talk on the efficacy outcomes. These were all very favorable, even astonishingly so.

Both WOMAC and KOOS scores improved by about 25 points, or approximately half of their baseline values after 6 months. Some improvement was also seen with placebo, but this still left a clinically and statistically significant advantage of 15 points in WOMAC scores and 20-21 points on KOOS. Self-rated pain scores fell 40-44 points from baseline with the two OSCA doses, with differences from placebo of 24-29 points. For the latter outcome, the lower dose outperformed the higher one to a small degree.

Another symptom-focused analysis looked at responses by OMERACT-OARSI criteria, achieved by 77-78% of the OSCA groups versus 39% of the placebo group. Park pointed out that this gap was already apparent just 4 weeks after dosing.

Structural effects were evaluated with the so-called MOCART and WORMS techniques for interpreting MRI images. The former examines cartilage specifically, while the latter was used to assess tibial and femoral bone marrow. The MOCART analysis showed some modest cartilage regeneration -- also greatest with the lower OSCA dose -- and a degree of marrow normalization. For the latter, the higher dose had the greater impact. Notably, the placebo group saw progression of both cartilage and marrow damage.

Finally, serum and urine biomarkers for inflammation and cartilage pathology all showed improvement. For these analyses, the higher dose appeared superior.

Being such a small and short-duration study, many questions remain unanswered. Patients in the current trial will be followed for an additional 6 months, plus a 5-year extension. Those data will give some insight into the therapy's durability. An issue for future studies will surely be whether repeat dosing is needed to maintain or boost structural recovery. Also, the current trial enrolled patients with moderate knee OA, so whether it's more or less effective in patients with milder or more severe disease is another issue that clinicians will want addressed.

Future plans by the developer, Korea-based Kangstem Biotech, aren't yet clear -- a July press release on the study's topline results indicated that the firm is seeking partnerships with global pharmaceutical companies, while making no mention of possible phase III trials.

来源:MedPage Today · medpagetoday.com